CMML: decitabine shows efficacy, even in proliferative disease

Access to the full content of this site is available only to registered healthcare professionals. Register to read more


  • Decitabine (Dacogen) demonstrated encouraging efficacy in patients with chronic myelomonocytic leukemia (CMML), including patients with proliferative disease.

Why this matters

  • CMML is associated with poor prognosis.
  • Hematopoietic stem cell transplant is currently the only potentially curative treatment option.

Study design

  • Phase 2 study to investigate the safety and efficacy of decitabine in 43 patients with CMML; two-thirds of patients had proliferative disease.
  • Funding: Fondazione Italiana Sindromi Mielodisplastiche Onlus (FISMOnlus).

Key results

  • Median of 6 treatment cycles.
  • 62% received all 6 cycles.
  • 47.6% response, but onl...